After investing heavily in both mechanisms for IO-IO combinations, Merck is cutting its losses with vibostolimab and favezelimab, and switching its anticancer bets to other modalities.
Once a key part of its next-generation plans in cancer, Merck & Co. has called a halt to the last remaining Phase III studies of its TIGIT- and LAG-3 targeting immunotherapy assets.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Novotech's CEO talks about rising interest for trials in regions with “regulatory agility” and “strategic insulation” from geopolitical complexity, especially among emerging and mid-sized biotech sponsors. Operational "reassessment” among some sponsors on exposure to China-based CROs/CRDMOs is another area he discussed.
Akeso’s penpulimab will be the second to hit the US market for nasopharyngeal carcinoma, but the first to win FDA approval for the indication based on clinical findings in US patients.
The Belgium-based firm will take the first-in-class drug, based on tick saliva, targets inflammation without increasing bleeding, into a Phase IIb trial is in preparation, supported by a new series B funding round.
CFO François Roger tells Scrip the French drugmaker is flexible geographically on making investments but its spend in the US has risen regardless of the threat of tariffs.
Evaluate's top five unpartnered clinical oncology assets reveals you have to get in early to snap up innovation in the competitive cancer space.
BriaCell announced its cell therapy Bria-IMT plus checkpoint inhibitors bested Gilead’s Trodelvy in a Phase II trial in HR+ breast cancer; a Phase III trial is enrolling.
The company is planning to start a registrational program on its home turf in Australia and is planning to bring the therapy to the US as well.
